SEC filing · 8-K

Hemab Therapeutics Holdings, Inc.: Executive or director change

Hemab Therapeutics elected Keli Walbert to its Board of Directors and Audit Committee.

Filed September 24, 2026

Neutral news

What happened

On September 24, 2026, the Board elected Keli Walbert as a Class I director and member of the Audit Committee.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Hemab Therapeutics Holdings, Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.